Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oxford Biomedica PLC Director's Dealing 2017

Sep 5, 2017

5190_dirs_2017-09-05_b626b193-5456-4221-aa26-35e48813ec52.html

Director's Dealing

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8619P

Oxford Biomedica PLC

05 September 2017

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

1 Issuer Oxford BioMedica PLC
2 Reason for notification Notification relates to DTR 3.1.2R
3 Name of PDMR Martin Diggle
4 Connected person Notification relates to following connected persons:

Vulpes Testudo Fund
5 Notification in respect of Notification in respect of holdings of persons in 4 above
6 Description of shares Oxford BioMedica PLC ordinary shares of 1p each
7 Name of registered shareholders and number of shares Vulpes Life Sciences Fund - 549,932,000 shares

Vulpes Testudo Fund - 30,956,834 shares
8 Nature of transaction Acquisition and Disposal
9 Number of shares acquired Vulpes Testudo Fund - 320,000 shares
10 Percentage of issued class acquired Vulpes Testudo Fund- 0.01%
11 Shares disposed Vulpes Testudo Fund - 300,000
12 Percentage of issued class disposed Vulpes Testudo Fund - 0.01%
13/14 Price per share of transactions, and date Vulpes Testudo Fund

Sold     300,000 shares @ £0.097,   01 Sep 2017

Bought 320,000 shares @ £0.094,   01 Sep 2017
15 Total holding following notification and total percentage holding following notification Vulpes Life Sciences Fund - 549,932,000 shares

17.7%

Vulpes Testudo Fund - 30,976,434 shares

1.0%
16 Date issuer informed 05 Sep 2017
23 Any additional information None
24 Contact name and telephone number S. Paynter, Chief Financial Officer

Oxford BioMedica

+44 (0)1865 783000

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBGGDCRXGBGRU